Carfilzomib showed more activity in CR cells in the MUC20‐OE xenograft MCL model compared to in the CR xenograft model and MUC20‐OE xenograft MCL model treated with vehicle (Figure 3E). This evidence concerns the gene MUC20 and mantle cell lymphoma.